Study to Assess Efficacy and Safety of XC221 200 mg in the Treatment of Influenza or Other ARVI

Clinical trial NCT03830905 · COMPLETED

Trial details

NCT number: NCT03830905
Sponsor: PHARMENTERPRISES LLC
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Influenza Acute Respiratory Viral Infections

Start date: 2019-01-31
Primary completion: 2019-07-03
Enrollment: 120

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.